Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer

D de Wit, T C Schneider, D J A R Moes, C F M Roozen, J den Hartigh, H Gelderblom, H J Guchelaar, J J van der Hoeven, T P Links, E Kapiteijn, N P van Erp, D de Wit, T C Schneider, D J A R Moes, C F M Roozen, J den Hartigh, H Gelderblom, H J Guchelaar, J J van der Hoeven, T P Links, E Kapiteijn, N P van Erp

Abstract

Background: Everolimus is a mTOR inhibitor used for the treatment of different solid malignancies. Many patients treated with the registered fixed 10 mg dose once daily are in need of dose interruptions, reductions or treatment discontinuation due to severe adverse events. This study determined the correlation between systemic everolimus exposure and toxicity. Additionally, the effect of different covariates on everolimus pharmacokinetics (PK) was explored.

Methods: Forty-two patients with advanced thyroid carcinoma were treated with 10 mg everolimus once daily. Serial pharmacokinetic sampling was performed on days 1 and 15. Subsequently, a population PK model was developed using NONMEM to estimate individual PK values used for analysis of an exposure-toxicity relationship. Furthermore, this model was used to investigate the influence of patient characteristics and genetic polymorphisms in genes coding for enzymes relevant in everolimus PK.

Results: Patients who required a dose reduction (n = 18) due to toxicity at any time during treatment had significant higher everolimus exposures [mean AUC0-24 (SD) 600 (274) vs. 395 (129) µg h/L, P = 0.008] than patients without a dose reduction (n = 22). A significant association between everolimus exposure and stomatitis was found in the four-level ordered logistic regression analysis (P = 0.047). The presence of at least one TTT haplotype in the ABCB1 gene was associated with a 21 % decrease in everolimus exposure.

Conclusion: The current study showed that dose reductions and everolimus-induced stomatitis were strongly associated with systemic everolimus drug exposure in patients with cancer. Our findings confirm observations from another study in patients with cancer and show us that everolimus is a good candidate for individualized dosing in patients with cancer. CLINICALTRIAL.

Gov number: NCT01118065.

Keywords: Everolimus; Exposure–toxicity; Individualized dosing; Pharmacogenetics; Population pharmacokinetics.

Figures

Fig. 1
Fig. 1
Visual predictive check (VPC) of final everolimus PK model
Fig. 2
Fig. 2
Boxplot of everolimus exposure in patient with and without dose reduction. a AUC0–24 and bCtrough
Fig. 3
Fig. 3
Boxplot of severity of stomatitis versus everolimus exposure. a AUC0–24 and bCtrough

References

    1. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27:2278–2287. doi: 10.1200/JCO.2008.20.0766.
    1. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–529. doi: 10.1056/NEJMoa1109653.
    1. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–456. doi: 10.1016/S0140-6736(08)61039-9.
    1. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–523. doi: 10.1056/NEJMoa1009290.
    1. European Medicine Agency (EMA) (2010) Afinitor® (everolimus): European Public Assessment Report (EPAR). . Accessed 1 Mar 2015
    1. Aapro M, Andre F, Blackwell K, et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol. 2014;25:763–773. doi: 10.1093/annonc/mdu021.
    1. Moes DJ, Press RR, den Hartigh J, et al. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin Pharmacokinet. 2012;51:467–480. doi: 10.2165/11599710-000000000-00000.
    1. O’Donnell A, Faivre S, Burris HA, III, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008;26:1588–1595. doi: 10.1200/JCO.2007.14.0988.
    1. European Medicine Agency (EMA) (2011) Guideline on bioanalytical method validation
    1. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83–95. doi: 10.2165/00003088-200443020-00002.
    1. Istrate MA, Nussler AK, Eichelbaum M, et al. Regulation of CYP3A4 by pregnane X receptor: the role of nuclear receptors competing for response element binding. Biochem Biophys Res Commun. 2010;393:688–693. doi: 10.1016/j.bbrc.2010.02.058.
    1. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24:25–36. doi: 10.2133/dmpk.24.25.
    1. Ravaud A, Urva SR, Grosch K, et al. Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology. Eur J Cancer. 2014;50:486–495. doi: 10.1016/j.ejca.2013.11.022.
    1. Tanaka C, O’Reilly T, Kovarik JM, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol. 2008;26:1596–1602.
    1. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008;26:1603–1610. doi: 10.1200/JCO.2007.14.5482.
    1. de Wit D, Guchelaar HJ, den Hartigh J, et al. Individualized dosing of tyrosine kinase inhibitors: are we there yet? Drug Discov Today. 2015;20:18–36. doi: 10.1016/j.drudis.2014.09.007.
    1. Yu H, Steeghs N, Nijenhuis CM, et al. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet. 2014;53:305–325. doi: 10.1007/s40262-014-0137-2.
    1. Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, et al. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer. 2014;110:2441–2449. doi: 10.1038/bjc.2014.194.
    1. Verheijen R, Bins S, Gadellaa-van Hooijdonk CG et al (2014) Individualized pharmacokinetically-guided dosing of pazopanib: a feasibility study in cancer patients. In: ESMO meeting 2014; abstract no. 7651
    1. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189–199. doi: 10.1067/mcp.2001.117412.
    1. Hung CC, Tai JJ, Lin CJ, et al. Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics. 2005;6:411–417. doi: 10.1517/14622416.6.4.411.
    1. Wasilewska A, Zalewski G, Chyczewski L, et al. MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatr Nephrol. 2007;22:44–51. doi: 10.1007/s00467-006-0275-3.
    1. van Erp NP, Eechoute K, van der Veldt AAM, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol. 2009;27:4406–4412. doi: 10.1200/JCO.2008.21.7679.
    1. Aarnoudse AJ, Dieleman JP, Visser LE, et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics. 2008;18:299–305. doi: 10.1097/FPC.0b013e3282f70458.
    1. Budde K, Fritsche L, Waiser J, et al. Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients. Eur J Med Res. 2005;10:169–174.
    1. U.S. Food and Drug Administration (2009) Afinitor® (everolimus): drug approval report. . Accessed 5 May 2015
    1. Thiery-Vuillemin A, Mouillet G, Nguyen Tan HT, et al. Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 2014;73:999–1007. doi: 10.1007/s00280-014-2435-7.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever